盘点:miRNA 在眼科中研究进展

2018-10-21 MedSci MedSci原创

Exp Eye Res:MicroRNA-218-5p通过PI3K / Akt / mTOR信号通路靶向EGFR抑制翼状胬肉上皮细胞的迁移和增殖 天津市眼科医院的Han S等人近日在Exp Eye Res杂志上发表了一项重要工作。翼状胬肉是一种常见的眼表疾病,可引起各种眼表症状。微RNA在各种眼部疾病的发展中起重要作用。然而,对于microRNA在翼状胬肉中的发病机制中的作用很少研究。他

Exp Eye Res:MicroRNA-218-5p通过PI3K / Akt / mTOR信号通路靶向EGFR抑制翼状胬肉上皮细胞的迁移和增殖

天津市眼科医院的Han S等人近日在Exp Eye Res杂志上发表了一项重要工作。翼状胬肉是一种常见的眼表疾病,可引起各种眼表症状。微RNA在各种眼部疾病的发展中起重要作用。然而,对于microRNA在翼状胬肉中的发病机制中的作用很少研究。他们的研究旨在分析人的翼状胬肉组织和培养的人翼状胬肉上皮细胞(hPECs)中miR-218-5p与表皮生长因子受体(EGFR)之间的关系。另外,他们还首次发现EGFR / PI3K / Akt / mTOR信号通路在翼状胬肉中具有重要的作用。

研究者通过手术获得翼状胬肉组织和正常眼球结膜组织,并在体外培养原代hPEC。进行细胞转染后,使用实时定量PCR(qRT-PCR)、Western印迹、荧光素酶报告基因测定和Scratch Wound Healing Assay等实验进行研究。

他们的实验数据表明,与正常结膜组织相比,翼状胬肉组织中miR-218-5p表达量减少,而EGFR表达量增加。在转染的hPEC中,研究结果表明,上调miR-218-5p可以通过PI3K / Akt / mTOR信号途径来显着地抑制EGFR的表达水平。此外,使用miR-218-5p抑制剂处理后可以促进hPECs的迁移和增殖,使用miR-218-5p类似物处理后阻滞hPECs的迁移和增殖。同时,研究人员发现,敲除EGFR后显着抑制hPEC的迁移。

总之,他们认为,miR-218-5p在翼状胬肉组织和hPEC中可以通过PI3K / Akt / mTOR途径下调EGFR的表达,进而抑制hPEC的迁移和增殖。可以进行进一步的研究,探索microRNA-218-5p-EGFR-PI3K / Akt / mTOR信号通路对翼状胬肉治疗的潜在价值。

原文出处:Han, S., et al., MicroRNA-218-5p inhibit the migration and proliferation of pterygium epithelial cells by targeting EGFR via PI3K/Akt/mTOR signaling pathway. Exp Eye Res, 2018

Biochem Biophys Res Commun:眼细胞内的miR-211直接抑制FRS2信号传导诱导视网膜神经节细胞凋亡

宝鸡市中心医院眼科的Yang Jie 等近日在Biochem Biophys Res Commun发表了一篇文章,在这向工作中,他们研究发现,与正常房水样品相比,在患有青光眼的患者房水(AH)中miR-211的表达水平显着升高。

微小RNA(miRNA)可能是神经退行性疾病的重要调节因子。然而,对眼内细胞的miRNA研究,虽然已经发现可能是治疗青光眼的和有价值的治疗靶点,但整体仍处于早期阶段。

值得注意的是,氧化应激引起的miR-211通过抑制ERK的活性,增强P38的活性,可以使得高眼压引起的视网膜神经节细胞(RGCs)死亡增加。这是一种依赖序列互补的方式,直接下调成纤维细胞生长因子受体底物2(Frs2)信号通路而起作用的。为了进一步探索RGCs中miR-211上调和压力诱导的细胞死亡增加之间的基本联系,他们的研究发现,外源FRS2的异位表达足以中和miR-211诱导的细胞活力的下降,特别是在高眼压的RGC-5细胞中。

总之,他们的研究结果表明,miR-211通过调节Frs2信号,负向调节高眼压状态下的细胞存活,并且指出miR-211 / Frs2级联反应在调节青光眼发病机制的反馈调节作用。

原文出处:Yang, J., N. Wang, and X. Luo, Intraocular miR-211 exacerbates pressure-induced cell death in retinal ganglion cells via direct repression of FRS2 signaling. Biochem Biophys Res Commun, 2018.

Life Sci:MicroRNA-145通过调节TLR4 / NF-κB信号通路来减弱视网膜内皮细胞中高葡萄糖诱导的氧化应激和炎症反应

济宁市第一人民医院眼科的Hui Y近日在Life Sci 发表了一篇文章,他们研究了miR-145在糖尿病性视网膜病变(DR)中的作用,发现miR-145通过调节TLR4 / NF-κB信号通路来减弱视网膜内皮细胞中高葡萄糖诱导的氧化应激和炎症反应。

糖尿病性视网膜病变(DR)仍然是糖尿病人失明的主要原因。DR的发病是多因素造成的结果,其中视网膜内皮细胞(RECs)的过度应激氧化和凋亡起着至关重要的作用。在这项研究中,RECs用25mM葡萄糖处理3天,随后发现miR-145在高葡萄糖(HG)处理的REC中显着下调。过表达miR-145降低了HG诱导的细胞凋亡,同时也降低了REC分泌氧化应激和炎性细胞因子。此外,在HG处理的RECs中,miR-145过表达也减弱TLR4的表达和NF-κBp65核定位情况。萤光素酶报告基因检测表明,miR-145可特异性结合TLR4的3'UTR,并且过表达TLR4可以消除HG处理的REC中miR-145的作用。

因此,作者认为miR-145可能是糖尿病性视网膜病变(DR)的潜在治疗靶点。

原文出处:Hui, Y. and Y. Yin, MicroRNA-145 attenuates high glucose-induced oxidative stress and inflammation in retinal endothelial cells through regulating TLR4/NF-kappaB signaling. Life Sci, 2018.

Biochem Biophys Res Commun:抑制NKILA可以促进NFκB活化,保护视网膜色素上皮细胞免于缺氧损害

南京医科大学第一附属医院眼科的Zhou Q等人在Biochem Biophys Res Commun发表了一篇研究性论文,他们研究了与核因子-κB(NFκB)相互作用的LncRNA(NKILA)在缺氧处理的RPE细胞中的表达情况及潜在的功能。

持续的视网膜缺氧会引起视网膜色素上皮细胞(RPE)受损。缺氧可以诱导ARPE-19细胞和原代人RPE细胞中NKILA的表达、NKILA-IκBα结合和NFκB的活化。使用shRNA的方法,敲低NKILA,可以促进NFκB的活化,抑制RPE细胞的死亡和凋亡。相反,NKILA的外源性过表达,可以阻断缺氧诱导的NFκB活化,从而加剧了RPE细胞的凋亡。进一步的研究表明,缺氧可以下调RPE细胞中抗NKILA的 microRNA microRNA-103(miR-103)。转染miR-103可以阻断缺氧诱导的NKILA表达,也可以显着增强NFκB的活化,保护RPE细胞免于缺氧引起的损害。

总之,他们得出结论认为,缺氧诱导的NKILA表达可以负向调节NFκB,促进RPE细胞死亡。相反,抑制NKILA可以通过促进NFκB的活化来保护RPE细胞免于缺氧损害。

原文出处:Zhou, Q., et al., NKILA inhibition protects retinal pigment epithelium cells from hypoxia by facilitating NFkappaB activation. Biochem Biophys Res Commun, 2018.

Immunology:MicroRNA通过调节Th17 / Treg的平衡来影响自身免疫性疾病

中国科学院深圳先进技术研究院生物医学与生物技术研究所的Liu C近日在Immunology杂志上发表了一篇重要的综述文章,系统性的总结了微小RNA(miRNA)对Th17 / Treg平衡的调节作用,及在自身免疫性疾病中的作用。

Th17细胞和调节性T(Treg)细胞是两种不同的T细胞亚群,它们对免疫功能具有相反的作用。虽然Th17细胞是免疫应答中的关键效应物,并且在自身免疫和炎症的发展中起关键作用,但Treg细胞通过调节效应T细胞的活性来协调整体免疫应答并维持外周免疫耐受。然而,Th17和Treg细胞的发育途径是相互关联的,它们之间存在大量的命运可塑性。干扰Th17 / Treg平衡对于自身免疫性疾病的发展有利,如EAE和多发性硬化症等。微小RNA(miRNA)是小的非编码RNA分子,主要在转录后调节基因表达。最近,新出现的证据表明,miRNA通过调节Th17 / Treg平衡,在调节自身免疫疾病的发病机制中发挥重要作用。本综述系统性概述了失调的miRNA及其在自身免疫疾病中调节Th17 / Treg平衡中的功能。

原文出处:Liu, C., et al., MicroRNA-mediated Regulation of Th17/Treg Balance in Autoimmune Disease. Immunology, 2018.

Mol Ther Nucleic Acids:剪接体介导的前mRNA反式剪接可以修复CEP290 mRNA的表达异常

美国宾夕法尼亚大学佩雷尔曼医学院眼科学高级视网膜和眼科治疗中心的Dooley SJ近日在Mol Ther Nucleic Acids杂志上发表了一篇重要的文章,他们针对与Leber先天性黑蒙10型(LCA10)和包括Joubert综合征在内的几种综合征疾病,采用剪接体介导的前mRNA反式剪接策略,在体外细胞系中和体内小鼠模型中对CEP290进行编辑,证明有效。

对于使用重组腺相关病毒(AAV)进行眼部基因治疗,已有研究指出在视网膜疾病的一部分中是安全和有效的,这部分主要是由RPE65缺乏引起的视网膜色素变性和Leber先天性黑蒙(LCA)。同时,目前认为,基因治疗具有独特的优势和安全性,对其他几种疾病也具有疗效。然而,由AAV基因组的包装基因片段大小的能力,限制了对编码序列长度小于5000nt疾病的应用。最普遍的视网膜疾病是由于单基因遗传突变引起,而这不在AAV基因组的包装基因片段大小的范围内。

在这里,针对与Leber先天性黑蒙10型(LCA10)和包括Joubert综合征在内的几种综合征疾病,他们设计了剪接体介导的前mRNA反式剪接策略来回复CEP290的表达。他们使用该策略,在体外细胞系中和体内小鼠模型中对CEP290进行编辑,证明有效。

因此,他们认为,本研究首次研究了CEP290转录本的广泛编辑和体内光感受器中CEP290转录物编辑的可行性,为今后评估治疗效果研究铺平了道路。

原文出处:Dooley, S.J., et al., Spliceosome-Mediated Pre-mRNA trans-Splicing Can Repair CEP290 mRNA. Mol Ther Nucleic Acids, 2018. 12: p. 294-308.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2019-01-15 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-23 Homburg
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-22 lietome15

    好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-22 183****7028

    学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-22 phoebeyan520

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-22 phoebeyan520

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1930657, encodeId=4587193065e25, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Tue Jan 15 02:35:00 CST 2019, time=2019-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312355, encodeId=a98113123555f, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1381105, encodeId=81b513811052b, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Tue Oct 23 13:35:00 CST 2018, time=2018-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350139, encodeId=cdd135013940, content=好文,值得点赞!认真学习,应用于实践!谢谢分享给广大同好!, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30251637888, createdName=lietome15, createdTime=Mon Oct 22 09:24:29 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350131, encodeId=b87f3501314c, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/iaAVWEsIJUkA1ITy3uL0lhHUhyaJibWgFtH4KbJuaLbY2WUK33jgCFyoZ8Eqx7eE7hCuZhytc1C5GRrfjVXN8lYg/0, createdBy=fcb82149579, createdName=183****7028, createdTime=Mon Oct 22 09:05:11 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350110, encodeId=4e2a350110f6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:48 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350109, encodeId=3dd5350109a6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Mon Oct 22 00:06:31 CST 2018, time=2018-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=350098, encodeId=22f135009846, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Oct 21 23:18:05 CST 2018, time=2018-10-21, status=1, ipAttribution=)]
    2018-10-21 医者仁心5538

    学习了

    0

相关资讯

Sci Rep:研究揭示绿茶对口腔上皮细胞miRNA和微生物的影响

绿茶(GT)提取物或纯化儿茶素具有预防口腔癌和其他癌症并抑制啮齿动物模型中癌症进展的能力,但在人类中的作用存在争议。本研究旨在通过检查其对口腔上皮细胞的影响来了解对GT可变反应的来源。吸烟接触4周前后,测量吸烟者舌下上皮细胞RNA和舌和牙龈微生物群。GT消耗对口腔上皮中的miRNA表达产生不一致的影响。只有分析检验配对的miRNAs,显示GT暴露后发生变化和一致的表达,为GT对miRNA的影响提供

Oncogene:miR-96和RARγ信号途径能够调控雄激素信号和前列腺癌恶化

在前列腺癌(PCa)中,视黄酸受体γ(NR1B3/RARG编码RARγ)的表达通常是减少的。因此,有研究人员探究了RARγ表达减少后的细胞学和基因调控结果,并且确定了RARγ调控机制。在非恶性(RWPE-1和HPr1-AR)和恶性(LNCaP)前列腺模型中,RARG shRNA方法能够减少RARγ水平;且RARγ水平的减少,而不是添加外源维甲酸,能够对前列腺细胞的存活和基因的表达产生最大的影响。C

Adv Sci:基于石墨烯的miRNA转染可阻断前粘连蛋白融合增加骨形成和血管形成

本研究旨在设计一种石墨烯基miRNA转染药物递送系统用于抗吸收治疗。使用负载有miR-7b过表达质粒的聚乙烯亚胺(PEI)功能化的氧化石墨烯(GO)复合物开发了高效的非病毒基因递送系统。GO-PEI复合物在可接受的细胞毒性范围内表现出优异的转染效率。GO-PEI-miR-7b转染后miR-7b的过表达通过阻碍基本促融合分子树突细胞特异性跨膜蛋白的表达明显消除破骨细胞(OC)融合和骨吸收活性。然而,

Cell Death Dis:研究揭示miRNA在调节脂肪组织干细胞修复糖尿病伤口中的作用及机制

晚期糖基化终产物/晚期糖基化终产物受体(AGEs/AGER)相互作用触发活性氧(ROS)生成,激活下游信号通路,并诱导内皮祖细胞凋亡。许多研究揭示microRNA(miRNA)参与调节细胞内ROS产生和细胞凋亡。然而,很少有研究探讨miRNA在调节脂肪组织干细胞(ADSCs)修复糖尿病伤口中的作用,且相关的细胞机制尚不清楚。在这项研究中,将ADSCs暴露于AGEs,然后将AGER的siRNA转染到

Gastroenterology:MiRNA检测在巴雷特食管诊断中的应用

研究发现,巴雷特食管患者存在特异的MiRNA过表达现象,是有效的巴雷特食管诊断方法,其中MIR194表达增加可能通过表观遗传机制参与疾病的发生

Sci Rep:前列腺癌的4种MicroRNA诊断分析

全球每年诊断的前列腺癌男性数目高于100万,然而目前的诊断方式仍旧对明显的癌症的鉴定存在不足,并且更加可靠的早期生物诊断标记在前列腺癌患者临床治疗的改善方面也是必需的。MicroRNA(miRNAs)能够调控重要的细胞学过程/通路,并能导致癌症且在体液中稳定存在。最近,有研究人员在血浆中分析了372个癌症相关的miRNAs,分析的时间在治疗开始前(大约60%的患者)和治疗开始后及治疗期间(大约40